Semaglutide, a human GLP-1 receptor agonist (GLP-1RA) with 94% homology to native human GLP-1, has emerged as a transformative therapy for patients with type 2 diabetes (T2D), chronic kidney disease (CKD), obesity, cardiovascular disease (CVD), and metabolic dysfunction-associated steatohepatitis (MASH).^[1] Beyond effective glycemic control and weight reduction, semaglutide offers significant kidney and cardiovascular protection through both direct and indirect mechanisms. The Evaluate Renal Function with Semaglutide Once Weekly trial demonstrated that semaglutide significantly reduced the risk of major kidney outcomes, including kidney failure, death from kidney or cardiovascular causes, reduced albuminuria and major cardiovascular events.^[2] Indirect benefits are mediated through improved blood glucose control, lower blood pressure, weight loss, and reduced systemic inflammation. Evidence from the FLOW trial demonstrated that once-weekly subcutaneous semaglutide 1.0 mg significantly reduced the risk of kidney disease progression, cardiovascular death, and kidney-related death in patients with CKD and T2D receiving standard of care, making it the first GLP-1RA to show confirmed kidney benefits in a dedicated renal outcomes trial. The REMODEL trial further established direct renal protection by showing reduced kidney fat, decreased renal vascular resistance, stabilization of cortical fibrosis, improved kidney tissue structure and function, and favorable tissue-level gene reprogramming that lowers metabolic stress, inflammation, and fibrotic responses. Importantly, these renal and cardiovascular benefits are largely independent of changes in body weight and blood glucose, highlighting semaglutide's direct organ-protective effects. Available as the only oral GLP-1RA and as a once-weekly injectable formulation, semaglutide continues to expand therapeutic options for patients at high cardio-renal-metabolic risk.